Latigo Biotherapeutics
Clinical trials sponsored by Latigo Biotherapeutics, explained in plain language.
-
New drug LTG-001: first human tests begin in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study tests a new drug, LTG-001, in 204 healthy adults aged 18 to 55. The goal is to check the drug's safety, side effects, and how the body processes it when taken by mouth or through a vein. Participants receive either the drug or a placebo, and no direct healt…
Phase: PHASE1 • Sponsor: Latigo Biotherapeutics • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC
-
New pain drug candidate enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study tests a new oral drug, LTG-321, in 236 healthy adults aged 18 to 55 to see if it is safe and how the body processes it. Some participants will also take a cold pressor test to measure pain tolerance. The study does not aim to treat any disease, but to gathe…
Phase: PHASE1 • Sponsor: Latigo Biotherapeutics • Aim: Knowledge-focused
Last updated May 18, 2026 11:59 UTC